(NASDAQ: LNTH) Lantheus Holdings's forecast annual revenue growth rate of 8.54% is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 9.18%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.08%.
Lantheus Holdings's revenue in 2024 is $1,296,429,000.On average, 6 Wall Street analysts forecast LNTH's revenue for 2024 to be $98,271,334,925, with the lowest LNTH revenue forecast at $97,217,206,297, and the highest LNTH revenue forecast at $99,640,269,957. On average, 5 Wall Street analysts forecast LNTH's revenue for 2025 to be $103,681,770,199, with the lowest LNTH revenue forecast at $98,628,147,495, and the highest LNTH revenue forecast at $116,034,323,975.
In 2026, LNTH is forecast to generate $114,542,111,467 in revenue, with the lowest revenue forecast at $103,576,377,894 and the highest revenue forecast at $146,761,183,285.